-+ 0.00%
-+ 0.00%
-+ 0.00%

SCYNEXIS To Present Preclinical Data On Second Generation IV/Oral Fungerp SCY-247 At The European Society Of Clinical Microbiology And Infectious Diseases

Benzinga·04/08/2025 12:57:32
Listen to the news

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Vienna, Austria being held from April 11-15, 2025.

SCY-247 is being developed to address systemic fungal diseases, with a key focus on invasive fungal infections where resistance to current limited treatment options is a significant concern. These presentations at ESCMID Global 2025 continue to build upon SCY-247's positive preclinical data illustrating its unique attributes in the fight against difficult-to-treat fungal infections, including its potent antifungal activity against multi drug-resistant fungi.